Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in Phase 3 clinical trials despite a recent multi-country cruise ship outbreak reported by WHO and CDC on May 2, with eight cases and three deaths. Official sources like CDC confirm no licensed vaccine exists for hantaviruses causing pulmonary syndrome in the Americas, such as Sin Nombre or Andes virus, while early-phase DNA vaccines (e.g., for Hantaan, Puumala, Andes) completed Phase 1/2a years ago but stalled without advancement. Renewed preclinical efforts by groups like University of Bath and USAMRIID highlight promise, yet experts note full trials could take a decade absent emergency acceleration; watch for FDA updates or outbreak escalations that might shift timelines.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$80,717 Vol.
$80,717 Vol.
31. Dez. 2026
$80,717 Vol.
$80,717 Vol.
31. Dez. 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in Phase 3 clinical trials despite a recent multi-country cruise ship outbreak reported by WHO and CDC on May 2, with eight cases and three deaths. Official sources like CDC confirm no licensed vaccine exists for hantaviruses causing pulmonary syndrome in the Americas, such as Sin Nombre or Andes virus, while early-phase DNA vaccines (e.g., for Hantaan, Puumala, Andes) completed Phase 1/2a years ago but stalled without advancement. Renewed preclinical efforts by groups like University of Bath and USAMRIID highlight promise, yet experts note full trials could take a decade absent emergency acceleration; watch for FDA updates or outbreak escalations that might shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Markt eröffnet: May 4, 2026, 10:39 AM ET
Volumen
$80,717Enddatum
31. Dez. 2026Markt eröffnet
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in Phase 3 clinical trials despite a recent multi-country cruise ship outbreak reported by WHO and CDC on May 2, with eight cases and three deaths. Official sources like CDC confirm no licensed vaccine exists for hantaviruses causing pulmonary syndrome in the Americas, such as Sin Nombre or Andes virus, while early-phase DNA vaccines (e.g., for Hantaan, Puumala, Andes) completed Phase 1/2a years ago but stalled without advancement. Renewed preclinical efforts by groups like University of Bath and USAMRIID highlight promise, yet experts note full trials could take a decade absent emergency acceleration; watch for FDA updates or outbreak escalations that might shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volumen
$80,717Enddatum
31. Dez. 2026Markt eröffnet
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the absence of any candidates in Phase 3 clinical trials despite a recent multi-country cruise ship outbreak reported by WHO and CDC on May 2, with eight cases and three deaths. Official sources like CDC confirm no licensed vaccine exists for hantaviruses causing pulmonary syndrome in the Americas, such as Sin Nombre or Andes virus, while early-phase DNA vaccines (e.g., for Hantaan, Puumala, Andes) completed Phase 1/2a years ago but stalled without advancement. Renewed preclinical efforts by groups like University of Bath and USAMRIID highlight promise, yet experts note full trials could take a decade absent emergency acceleration; watch for FDA updates or outbreak escalations that might shift timelines.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen